Ridge Preservation Using Demineralized Bone Matrix Gel With Recombinant Human Bone Morphogenetic Protein-2 After Tooth Extraction: A Randomized Controlled Clinical Trial

• Published in: Journal of oral and maxillofacial surgery Vol. 72; no. 7; pp. 1281 - 1290
• Main Authors: Kim, Yu-Jin, Lee, Jeong-Yol, Kim, Jong-Eun, Park, Jung-Chul, Shin, Sang-Wan, Cho, Kyoo-Sung
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2014
• Subjects: Adult; Alveolar Bone Loss - prevention & control; Alveolar Process - diagnostic imaging; Alveolar Process - surgery; Bone Morphogenetic Protein 2 - administration & dosage; Bone Morphogenetic Protein 2 - therapeutic use; Female; Humans; Male; Middle Aged; Prospective Studies; Recombinant Proteins - administration & dosage; Recombinant Proteins - therapeutic use; Single-Blind Method; Surgery; Tomography, X-Ray Computed; Tooth Extraction - adverse effects; Transforming Growth Factor beta - administration & dosage; Transforming Growth Factor beta - therapeutic use
• ISSN: 0278-2391; 1531-5053; 1531-5053
• DOI: 10.1016/j.joms.2014.01.022

The aim of the present randomized controlled trial was to determine the safety and efficacy of injectable demineralized bone matrix (DBM) gel combined with recombinant human bone morphogenetic protein-2 (rhBMP-2) on alveolar ridge preservation after tooth extraction. A total of 69 patients were randomly assigned to either a test group (n = 35) or a control group (n = 34). In the test group, DBM, together with rhBMP-2 (0.05 mg/mL; rhBMP-2/DBM) was transplanted into the extraction sockets. The control group received DBM alone. The safety of rhBMP-2/DBM was evaluated by oral examination, serum chemistry, and hematologic examination. The radiographic changes in alveolar bone height and width were measured using computed tomography scans performed immediately after transplant and again 3 months thereafter. Healing was uneventful in all subjects, with no anticipated adverse events and no clinically significant changes in the serum chemistry and hematologic findings. No meaningful immune response was found among the study groups. No significant difference was found in the radiographic changes of alveolar bone height and width (P > .05). This new injectable biomaterial can be used easily and safely in clinical applications.